Gavi Alliance, operating under the name Gavi The Vaccine Alliance, is located in Washington, DC. The organization was established in 2009. According to its NTEE Classification (Q33) the organization is classified as: International Relief, under the broad grouping of International, Foreign Affairs & National Security and related organizations. As of 12/2023, Gavi The Vaccine Alliance employed 20 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Gavi The Vaccine Alliance is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Gavi The Vaccine Alliance generated $2.6b in total revenue. This organization has experienced exceptional growth, as over the past 5 years, it has increased revenue by an average of 24.5% each year . All expenses for the organization totaled $3.7b during the year ending 12/2023. While expenses have increased by 27.5% per year over the past 5 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2020, Gavi The Vaccine Alliance has awarded 124 individual grants totaling $425,597,927. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990T
Mission & Program ActivityExcerpts From the 990T Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
TO SAVE LIVES & PROTECT PEOPLE'S HEALTH BY INCREASING EQUITABLE AND SUSTAINABLE USE OF VACCINES.
Describe the Organization's Program Activity:
THE VACCINE GOAL: INTRODUCE AND SCALE UP VACCINESWITH THE EXCEPTION OF PENTAVALENT VACCINE, IN AGGREGATE ALL GAVI-SUPPORTED VACCINES HAD HIGHER COVERAGE IN 2023 THAN BEFORE THE PANDEMIC IN 2019.- 34 GAVI-SUPPORTED VACCINE INTRODUCTIONS AND PREVENTIVE CAMPAIGNS TOOK PLACE IN 2023 IN ADDITION TO 40 OUTBREAK RESPONSE VACCINATION CAMPAIGNS SUPPORTED BY GAVI.- 14 MILLION GIRLS FULLY IMMUNIZED AGAINST HPV WITH GAVI SUPPORT IN 2023 MORE THAN THE PREVIOUS TEN YEARS COMBINED.- 15 COUNTRIES ACCESSED CHOLERA, MENINGOCOCCAL AND YELLOW FEVER VACCINES THROUGH GAVI-SUPPORTED EMERGENCY STOCKPILES A TOTAL OF 29 TIMES IN 2023.- 57 GAVI-SUPPORTED COUNTRIES INCREASED BREADTH OF PROTECTION WITH VACCINES IN THE GAVI PORTFOLIO TO 56%, UP 3 PERCENTAGE POINTS FROM 2022.THE EQUITY GOAL: STRENGTHEN HEALTH SYSTEMS TO INCREASE EQUITY IN IMMUNIZATIONIN GAVI 5.0/5.1, HEALTH SYSTEM STRENGTHENING (HSS) SUPPORT PRIORITIZES EQUITY IN IMMUNISATION DELIVERY, TO REDUCE THE NUMBER OF ZERO-DOSE AND UNDER-IMMUNIZED CHILDREN.- >69 MILLION CHILDREN WERE REACHED WITH GAVI-SUPPORTED ROUTINE VACCINES IN 2023 MORE THAN IN ANY YEAR APART FROM 2019.- 47 COUNTRIES HAVE INSTALLED MORE THAN 67,000 COLD CHAIN EQUIPMENT (CCE) UNITS PROCURED BY UNICEF SUPPLY DIVISION THROUGH GAVI'S COLD CHAIN EQUIPMENT OPTIMIZATION PLATFORM (CCEOP) NEARLY 5,200 IN 2023 ALONE.- AFTER SEVERAL YEARS OF DECLINE SINCE 2019, AVERAGE COVERAGE OF DTP3 IN 26 LOW-INCOME COUNTRIES SUPPORTED BY GAVI HELD STEADY IN 2023 THE ONLY INCOME GROUP TO AVOID DECLINE.- 32 COUNTRIES WERE APPROVED FOR EQUITY ACCELERATOR FUND (EAF) FUNDING TO IDENTIFY AND REACH ZERO-DOSE CHILDREN AND MISSED COMMUNITIES.- IN 2023, GAVI-SUPPORTED COUNTRIES MAINTAINED DTP3 COVERAGE AT 80% (COMPARED TO THE 84% GLOBAL AVERAGE).THE SUSTAINABILITY GOAL: IMPROVE SUSTAINABILITY OF NATIONAL IMMUNIZATION PROGRAMSTHE YEAR 2023 CONFIRMED THE ROBUSTNESS OF THE VACCINE ALLIANCE'S CO-FINANCING APPROACH AND THE STEADY FINANCIAL COMMITMENT OF COUNTRIES, DESPITE MANY COUNTRIES FACING INCREASING FRAGILITY.- US$ 215 MILLION WAS CONTRIBUTED BY COUNTRIES TOWARDS THE CO-FINANCING OF GAVI-SUPPORTED VACCINES IN 2023 THE HIGHEST AMOUNT YET AND A TESTAMENT TO COUNTRY OWNERSHIP AND THE LONG-TERM FINANCIAL SUSTAINABILITY OF GAVI-SUPPORTED VACCINES.- 55 VACCINE PROGRAMS ORIGINALLY INTRODUCED WITH GAVI FUNDING ARE NOW SELF-FINANCED BY COUNTRIES AS OF 2023, UP FROM 40 IN 2018.- 100% OF COUNTRIES FULLY MET THEIR 2023 CO-FINANCING OBLIGATION EXCEPT FOUR WAIVERS FOR HUMANITARIAN CRISIS.- IN THE FACE OF FISCAL CHALLENGES, CLIMATE CHANGE, CONFLICT AND INSTABILITY, MOST GAVI-SUPPORTED COUNTRIES MAINTAINED OR INCREASED DOMESTIC RESOURCES FOR CO-FINANCING OF GAVI-SUPPORTED VACCINES IN 2023, BRINGING TO US$ 1.7 BILLION THEIR TOTAL CONTRIBUTION SINCE THE INTRODUCTION OF THE CO-FINANCING POLICY IN 2008.THE HEALTHY MARKETS GOAL: ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTSGAVI'S MARKET SHAPING EFFORTS MAKE LIFE-SAVING VACCINES AND OTHER IMMUNISATION PRODUCTS MORE ACCESSIBLE AND AFFORDABLE FOR LOWER-INCOME COUNTRIES.- 10 MARKETS FOR VACCINES AND IMMUNISATION PRODUCTS EXHIBITED ACCEPTABLE LEVELS OF HEALTHY MARKET DYNAMICS IN 2023, MEETING THE TARGET FOR THE YEAR.- 10 INNOVATIVE PRODUCTS WERE WITHIN THE PIPELINE OF COMMERCIAL-SCALE MANUFACTURERS IN 2023, CONTINUING TO EXCEED THE ALLIANCE TARGET OF 8 BY 2025 WELL AHEAD OF SCHEDULE..- 1 NEW PRODUCT WITH IMPROVED CHARACTERISTICS WAS NEWLY OFFERED TO GAVI-SUPPORTED COUNTRIES IN 2023, KEEPING THE ALLIANCE ON TRACK FOR ITS 2025 TARGET: MULTIVALENT MENINGOCOCCAL CONJUGATE VACCINE (MMCV), THE FIRST CONJUGATE VACCINE TO PROTECT AGAINST THE FIVE PREDOMINANT SEROGROUPS OF MENINGOCOCCAL MENINGITIS IN AFRICA.- THROUGH GAVI'S MARKET SHAPING EFFORTS, THE NUMBER OF MANUFACTURERS SUPPLYING PREQUALIFIED GAVI-SUPPORTED VACCINES REMAINED AT 19 IN 2023 (WITH MORE THAN HALF BASED IN LOW- AND MIDDLE-INCOME COUNTRIES) COMPARED WITH 5 IN 2001.FURTHER INFORMATION ON GAVI'S PROGRESS TOWARDS ACHIEVING ITS STRATEGIC GOALS CAN BE FOUND IN ITS 2023 ANNUAL PROGRESS REPORT, ONLINE AT: HTTPS://WWW.GAVI.ORG/PROGRAMMES-IMPACT/OUR-IMPACT/PROGRESS-REPORTS.
COVAX CLOSED ON 31 DECEMBER 2023, AFTER HAVING DELIVERED NEARLY 2 BILLION COVID-19 VACCINE DOSES AND SAFE INJECTION DEVICES TO 146 ECONOMIES, AND IS ESTIMATED TO HAVE AVERTED OVER 2.7 MILLION DEATHS IN AMC LOWER-INCOME PARTICIPATING ECONOMIES. COVAX SUPPLIED 74% OF LOW-INCOME COUNTRIES' COVID-19 VACCINE DOSES DURING THE PANDEMIC; AND IN TOTAL, 54 OF THE 92 AMC-ELIGIBLE ECONOMIES RELIED ON COVAX FOR MORE THAN HALF OF THEIR COVID-19 VACCINE SUPPLY. COVAX HELPED LOWER-INCOME COUNTRIES ACHIEVE TWO-DOSE COVERAGE OF 57%, COMPARED TO THE GLOBAL AVERAGE OF 67%; AND PROTECT HIGH-RISK POPULATIONS: 85% OF HEALTH CARE WORKERS AND 72% OF OLDER ADULTS (COMPARED TO HIGH-INCOME COUNTRIES AT 89% AND 95%, RESPECTIVELY).FURTHER INFORMATION ON GAVI'S COVAX REPORT CAN BE FOUND IN ITS 2023 ANNUAL PROGRESS REPORT, ONLINE AT: HTTPS://WWW.GAVI.ORG/PROGRAMMES-IMPACT/OUR-IMPACT/PROGRESS-REPORTS.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Jose Manuel Barroso Chair | Trustee | 2 | $0 |
Sarah Goulding Vice Chair - Until 12/23 | Trustee | 2 | $0 |
Omar Abdi Board Member | Trustee | 2 | $0 |
Kwaku Agyeman-Manu Board Member | Trustee | 2 | $0 |
Takeshi Akahori Board Member | Trustee | 2 | $0 |
Beth Arthy Board Member | Trustee | 2 | $0 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
Tech Mahindra Limited It Services | 12/30/23 | $5,984,697 |
Linklaters Llp Legal Services | 12/30/23 | $2,691,045 |
Helvetic Payroll Sa Temporary Staffing (Salary Hosting) | 12/30/23 | $6,638,165 |
The Boston Consulting Group And Cie Consulting Services | 12/30/23 | $2,041,035 |
Michael Page International Suisse Temporary Staffing | 12/30/23 | $2,030,114 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $377,735,536 |
Government grants | $1,862,274,293 |
All other contributions, gifts, grants, and similar amounts not included above | $30,143,759 |
Noncash contributions included in lines 1a–1f | $309,627,599 |
Total Revenue from Contributions, Gifts, Grants & Similar | $2,270,153,588 |
Total Program Service Revenue | $0 |
Investment income | $349,559,545 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $1,603,432 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $2,630,210,671 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $125,267,680 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $3,399,136,014 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $3,471,262 |
Compensation of current officers, directors, key employees. | $920,233 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $54,789,696 |
Pension plan accruals and contributions | $11,477,990 |
Other employee benefits | $14,159,658 |
Payroll taxes | $1,424,947 |
Fees for services: Management | $0 |
Fees for services: Legal | $1,261,895 |
Fees for services: Accounting | $713,382 |
Fees for services: Lobbying | $277,200 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $5,257,297 |
Fees for services: Other | $60,428,027 |
Advertising and promotion | $893,025 |
Office expenses | $6,870,007 |
Information technology | $4,294,950 |
Royalties | $0 |
Occupancy | $4,828,119 |
Travel | $7,517,093 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $4,394,851 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $1,065,059 |
Insurance | $766,452 |
All other expenses | $1,305,185 |
Total functional expenses | $3,709,599,789 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $14,300,731 |
Savings and temporary cash investments | $6,808,004,210 |
Pledges and grants receivable | $1,506,164,534 |
Accounts receivable, net | $0 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $154,105,390 |
Net Land, buildings, and equipment | $1,455,031 |
Investments—publicly traded securities | $0 |
Investments—other securities | $1,301,455,921 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $515,760,750 |
Total assets | $10,301,246,567 |
Accounts payable and accrued expenses | $230,456,601 |
Grants payable | $463,446,843 |
Deferred revenue | $1,067,371,453 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $1,044,655,248 |
Total liabilities | $2,805,930,145 |
Net assets without donor restrictions | $1,761,702,186 |
Net assets with donor restrictions | $5,733,614,236 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $10,301,246,567 |
Over the last fiscal year, Gavi Alliance has awarded $125,267,396 in support to 34 organizations.
Grant Recipient | Amount |
---|---|
CAMPAIGN FOR TOBACCO-FREE KIDS PURPOSE: PARTNER SUPPORT | $654,105 |
CDC PURPOSE: PARTNER SUPPORT | $644,000 |
CDC FOUNDATION PURPOSE: PARTNER SUPPORT | $1,199,922 |
CLINTON HEALTH ACCESS INITIATIVE PURPOSE: PARTNER SUPPORT | $5,763,165 |
DIMAGI INC PURPOSE: PARTNER SUPPORT | $55,000 |
FAMILY HEALTH INTERNATIONAL PURPOSE: PARTNER SUPPORT | $340,225 |